Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 35Prostatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 15Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Carcinoma, Ovarian Epithelial 7Adenocarcinoma of Lung 7Inflammatory Breast Neoplasms 6Fallopian Tube Neoplasms 6Breast Neoplasms, Male 6Stomach Neoplasms 4Head and Neck Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Tongue Neoplasms 3Pain 3Neoplasm Metastasis 3Adenocarcinoma, Bronchiolo-Alveolar 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Pleural Effusion, Malignant 2Oropharyngeal Neoplasms 2Neoplasms 2Lymphoid Interstitial Pneumonia 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma 2Brenner Tumor 2

Interventions

Taxes 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1CTLA-4 Antigen 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma, Mucinous × Docetaxel × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡